Daniel C. Maneval PhD

Scientific leader with extensive experience in small/emerging biotech companies and biopharmaceutical organizations. Expertise in oncology, gene therapy, drug delivery, and pharmacokinetics with contributions to all stages of drug development from IND (e.g., Herceptin®, Adstiladrin® gene therapy) through BLA and US/EU approval (e.g., HYQVIA™, HYLECTA™)